FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities ; volume:14 ; number:1 ; day:3 ; month:6 ; year:2014 ; pages:1-6 ; date:12.2014
BMC cancer ; 14, Heft 1 (3.6.2014), 1-6, 12.2014
- Urheber
-
L’Abbate, Alberto
- Beteiligte Personen und Organisationen
-
Lo Cunsolo, Crocifissa
Macrì, Ettore
Iuzzolino, Paolo
Mecucci, Cristina
Doglioni, Claudio
Coco, Michelina
Muscarella, Lucia Anna
Salati, Simona
Tagliafico, Enrico
Minoia, Carla
De Tullio, Giacoma
Guarini, Attilio
Testoni, Nicoletta
Agostinelli, Claudio
Storlazzi, Clelia Tiziana
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-396
- URN
-
urn:nbn:de:1111-2016030415225
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- L’Abbate, Alberto
- Lo Cunsolo, Crocifissa
- Macrì, Ettore
- Iuzzolino, Paolo
- Mecucci, Cristina
- Doglioni, Claudio
- Coco, Michelina
- Muscarella, Lucia Anna
- Salati, Simona
- Tagliafico, Enrico
- Minoia, Carla
- De Tullio, Giacoma
- Guarini, Attilio
- Testoni, Nicoletta
- Agostinelli, Claudio
- Storlazzi, Clelia Tiziana
- SpringerLink (Online service)
Ähnliche Objekte (12)
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
Chronic myeloproliferative disorders : cytogenetic and molecular genetic abnormalities ; 18 tables
Cytogenetic abnormalities and fragile-x syndrome in Autism Spectrum Disorder
Cytogenetic abnormalities in a sample of females with premature ovarian failure
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Sieg Sonderkarte 5q
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
Chronic myeloproliferative disorders : cytogenetic and molecular genetic abnormalities ; 18 tables
Cytogenetic abnormalities and fragile-x syndrome in Autism Spectrum Disorder
Cytogenetic abnormalities in a sample of females with premature ovarian failure
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Sieg Sonderkarte 5q
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
Chronic myeloproliferative disorders : cytogenetic and molecular genetic abnormalities ; 18 tables
Cytogenetic abnormalities and fragile-x syndrome in Autism Spectrum Disorder
Cytogenetic abnormalities in a sample of females with premature ovarian failure
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Sieg Sonderkarte 5q